Abstract: There is a need for high-order frequency measurement without greatly increasing consumption currents and chip die sizes. A semiconductor device includes: an electric power measuring portion that performs electric power measurement; a high-order frequency measuring portion that performs high-order frequency measurement; and a clock controller that supplies an electric power measuring portion with a first clock signal at a first sampling frequency and supplies a high-order frequency measuring portion with a second clock signal at a second sampling frequency. The second sampling frequency is higher than the first sampling frequency.

Abstract: There is a need for high-order frequency measurement without greatly increasing consumption currents and chip die sizes. A semiconductor device includes: an electric power measuring portion that performs electric power measurement; a high-order frequency measuring portion that performs high-order frequency measurement; and a clock controller that supplies an electric power measuring portion with a first clock signal at a first sampling frequency and supplies a high-order frequency measuring portion with a second clock signal at a second sampling frequency. The second sampling frequency is higher than the first sampling frequency.

Abstract: A microneedle array is provided which has (1) the strength to withstand insertion into the skin surface layer and/or stratum corneum, (2) the fineness and flexibility to cause no pain or bleeding in the skin surface layer and/or stratum corneum at the insertion site of the microneedles, and (3) solubility or biodegradability of the microneedle portions under the skin. The microneedle array is produced by forming microneedles using proteoglycan as a base material.

Abstract: An operation clock generation circuit performs a calculation on the basis of the frequency errors of a fundamental clock and the clock pulses of the fundamental clock, and generates an operation clock obtained by correcting the frequency errors at first intervals. A correction clock generation circuit converts a lower-bit value that is a value represented by the bits lower than the predefined bit used for judging the change of the state of the operation clock into a count number of the clock pulses of a second clock whose frequency is higher than that of the operation clock, generates a correction clock obtained by correcting the operation clock on the basis of a time required for counting the count number of the clock pulses and the clock pulses of the operation clock.

Abstract: An operation clock generation circuit performs calculation on the basis of the frequency errors of a fundamental clock and the clock pulses of the fundamental clock, and generates an operation clock obtained by correcting the frequency errors at first intervals. A correction clock generation circuit converts a lower-bit value that is a value represented by the bits lower than the predefined bit used for judging the change of the state of the operation clock into a count number of the clock pulses of a second clock whose frequency is higher than that of the operation clock, generates a correction clock obtained by correcting the operation clock on the basis of a time required for counting the count number of the clock pulses and the clock pulses of the operation clock.

Abstract: An operation clock generation circuit performs calculation on the basis of the frequency errors of a fundamental clock and the clock pulses of the fundamental clock, and generates an operation clock obtained by correcting the frequency errors at first intervals. A correction clock generation circuit converts a lower-bit value that is a value represented by the bits lower than the predefined bit used for judging the change of the state of the operation clock into a count number of the clock pulses of a second clock whose frequency is higher than that of the operation clock, generates a correction clock obtained by correcting the operation clock on the basis of a time required for counting the count number of the clock pulses and the clock pulses of the operation clock.

Abstract: An operation clock generation circuit performs a calculation on the basis of the frequency errors of a fundamental clock and the clock pulses of the fundamental clock, and generates an operation clock obtained by correcting the frequency errors at first intervals. A correction clock generation circuit converts a lower-bit value that is a value represented by the bits lower than the predefined bit used for judging the change of the state of the operation clock into a count number of the clock pulses of a second clock whose frequency is higher than that of the operation clock, generates a correction clock obtained by correcting the operation clock on the basis of a time required for counting the count number of the clock pulses and the clock pulses of the operation clock.

Abstract: An operation clock generation circuit performs a calculation on the basis of the frequency errors of a fundamental clock and the clock pulses of the fundamental clock, and generates an operation clock obtained by correcting the frequency errors at first intervals. A correction clock generation circuit converts a lower-bit value that is a value represented by the bits lower than the predefined bit used for judging the change of the state of the operation clock into a count number of the clock pulses of a second clock whose frequency is higher than that of the operation clock, generates a correction clock obtained by correcting the operation clock on the basis of a time required for counting the count number of the clock pulses and the clock pulses of the operation clock.

Abstract: An object of the present invention is to provide a novel microneedle array that has (1) the strength to withstand insertion into the skin surface layer and/or stratum corneum, (2) the fineness and flexibility to cause no pain or bleeding in the skin surface layer and/or stratum corneum at the insertion site of the microneedles, and (3) solubility or biodegradability of the microneedle portions under the skin. [Method for Achieving the Object] The microneedle array is produced by forming microneedles using proteoglycan as a base material.

Abstract: A homogeneous interleukin 1.beta. (IL-1.beta.), its derivative having a modified amino acid sequence of IL-1.beta., a gene coding for said derivative, medical composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.beta. and the derivative.

Abstract: This invention provides an anti-tumor agent and a method for treating a tumor wherein gamma-interferon and interleukin-1 are used as active ingredients.

Abstract: A homogeneous interleukin 1.beta. (IL-1.beta.), its derivative having a modified amino acid sequence of IL-1.beta., a gene coding for said derivative, medical composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.beta. and the derivative.

Abstract: The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a Il-1.alpha. derivative having an amino acid sequence of the formula (.alpha.) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.

Abstract: Methods are disclosed for promoting production of colony stimulating factor and inhibiting growth of Meth A tumor cells comprising administering a pharmaceutically effective amount of modified IL-1.alpha. to a subject.

Abstract: Apoptosis regulating compositions each comprising a member selected from a series of carbostyril derivatives and salts thereof, inclusive of carbostyril derivatives of general formula (1) ##STR1## and salts thereof, as an active ingredient are provided. The apoptosis regulating compositions of the invention are of use as anticancer agents, antiretrovirus agents, therapeutic agents for autoimmune diseases, therapeutic agents for thrombocytopenia, therapeutic agents for Alzheimer's disease, therapeutic agents for diseases of the liver, and cancer metastasis inhibitors, among others.

Abstract: Methods for stimulating immunity, inhibiting tumor growth, promoting production of a cytokine, and preventing or inhibiting radiation injury by administration of Interleukin-1.alpha. (IL-1.alpha.) derivatives, are disclosed.

Abstract: Apoptosis regulating compositions each comprising a member selected from a series of carbostyril derivatives and salts thereof, inclusive of carbostyril derivatives of general formula (1) ##STR1## and salts thereof, as an active ingredient are provided. The apoptosis regulating compositions of the invention are of use as anticancer agents, antiretrovirus agents, therapeutic agents for autoimmune diseases, therapeutic agents for thrombocytopenia, therapeutic agents for Alzheimer's disease, therapeutic agents for diseases of the liver, and cancer metastasis inhibitors, among others.

Abstract: An interleukin-1.alpha. (IL-1.alpha.) derivative having a modified amino acid sequence of IL-1.alpha., a gene coding for said derivative, medicinal composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.alpha..

Abstract: The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a IL-1.alpha. derivative having an amino acid sequence of the formula (.alpha.) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.

Abstract: An interleukin-1.alpha. (IL-1.alpha.) derivative having a modified amino acid sequence of IL-1.alpha., a gene coding for said derivative, medicinal composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.alpha..